CytoDyn Inc.

CytoDyn Inc.

Overview

CytoDyn is a clinical-stage biotechnology company developing leronlimab (PRO 140), a humanized monoclonal antibody that targets the CCR5 receptor. The company’s clinical development is focused on solid-tumor oncology, with ongoing and planned studies across multiple cancer indications. CytoDyn was originally incorporated in Colorado in 2002 as RexRay Corporation and reincorporated in Delaware in 2015. Its principal business office is in Vancouver, Washington. Filings include CytoDyn Inc. and its wholly owned subsidiary CytoDyn Operations Inc.

Key product and mechanism

• Product candidate: leronlimab (PRO 140), a monoclonal antibody that binds human CCR5.
• Proposed mechanism: blocks CCR5 signaling and may affect tumor cell migration and metastasis, immune cell trafficking within the tumor microenvironment, and interactions with chemotherapy and radiation-related pathways.
• Distinguishing features: targeted action on the second extracellular loop and N-terminus of CCR5; potential to reprogram the tumor microenvironment by affecting immune cell dynamics and PD-L1 expression on circulating tumor cells in some settings. Leronlimab is described as a competitive CCR5 inhibitor with selectivity that avoids CCR5 agonist activation.

Indications, pipeline, and development status

• Primary focus: solid-tumor oncology, currently emphasizing colorectal cancer (CRC) in combination with TAS-102 (trifluridine/tipiracil) and bevacizumab for patients with CCR5+ microsatellite-stable (MSS) relapsed/refractory metastatic CRC (mCRC). This program is called CLOVER (CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen).

• Other programs:

  • Metastatic triple-negative breast cancer (mTNBC): prior Phase 1b/2 and compassionate-use efforts; additional breast cancer studies expected to begin enrolling in 2026–2027.
  • Glioblastoma multiforme (GBM): preclinical and investigator-initiated pilot work in collaboration with academic centers; additional GBM projects planned within the next year.
  • Preclinical collaboration to develop longer-acting CCR5 antagonists using artificial intelligence tools in a joint development arrangement.

• Regulatory pathway: the company has engaged with the FDA on the CRC program and is pursuing appropriate regulatory strategies, which may include standard and expedited pathways such as Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review when applicable.

Recent corporate developments (2026 highlights)

• CLOVER trial: enrollment for the Phase 2 CLOVER study in CCR5+ MSS mCRC was completed on April 21, 2026, with just over 60 patients enrolled across multiple sites.
• AACR 2026: data presented April 19–21, 2026 showed evidence related to leronlimab’s role in solid-tumor oncology, including PD-L1 expression and immune interactions; a second abstract reported the Phase 2 study of leronlimab with TAS-102 and bevacizumab in mCRC.
• Expanded Access Program (EAP): initial dosing of the first participant in an EAP for patients with triple-negative breast cancer was completed on April 27, 2026.
• Investor communications: an investor update call on April 30, 2026 reviewed scientific, clinical, operational, and financial progress and outlined 2026 priorities.
• Strategic collaboration with Natera: on June 4, 2026 CytoDyn and Natera announced a collaboration to advance ctDNA-guided development and molecular response analysis in metastatic CRC. Natera will assess CLOVER samples and provide real-world data analyses from its oncology database of more than 2 million plasma timepoints.

Intellectual property

CytoDyn maintains a patent portfolio covering leronlimab (PRO 140) and related uses, including U.S. and international patents. Cited expiration references include product-related protection around 2032, cancer/MASH-related protection around 2040, and other cancer-use-related expirations extending into the mid-2040s. The company also references data exclusivity and trade secret protection, with potential regulatory exclusivities available under U.S. and other jurisdictions.

Regulatory landscape and compliance

The company’s strategy accounts for U.S. biologics regulation under the FDCA and PHSA and the BLA process, including INDs, clinical trial governance (GCP, IRB/IEC, DSMB), and post-approval requirements (cGMP, REMS, post-market studies). CytoDyn plans for potential expedited development pathways and recognizes emergency use provisions (EUAs) when applicable. Product exclusivity under the Biologics Price Competition and Innovation Act (BPCIA) and orphan drug designation/exclusivity are part of the regulatory framework. Manufacturing compliance, post-approval safety monitoring, and potential post-approval labeling or REMS actions are ongoing considerations.

Financial and operational outlook

• Regulatory and development-related fees referenced include PDUFA/FDA user fees for BLA submissions (an example cited: approximately $4.7 million for FY2026) and an annual program fee for a BLA (approximately $0.4 million per program).
• The company anticipates the need for additional funding to support continued clinical development, potential preclinical and clinical studies, and commercialization efforts, which may include non-dilutive financing and strategic partnerships.

Summary

CytoDyn is a clinical-stage biotech developing leronlimab (PRO 140) targeting CCR5, focused on solid-tumor oncology with a Phase 2 CLOVER program in CCR5+ MSS mCRC and additional programs in mTNBC and GBM. Key 2026 activities include CLOVER enrollment completion, AACR presentations, an Expanded Access Program for TNBC, and a ctDNA collaboration with Natera. Patent protection and regulatory strategy are central to the company’s plan, with multi-decade patent horizons cited for key leronlimab uses.